Welcome to our dedicated page for cbdMD news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on cbdMD stock.
cbdMD, Inc. reports developments in hemp-derived cannabinoid consumer products, including the cbdMD, Paw CBD, Bluebird Botanicals and Herbal Oasis brands.
Company news focuses on CBD product categories, THC-infused social seltzer distribution, clinical and regulatory science initiatives, acquisitions, financial results, liquidity, balance-sheet actions and exchange-listing compliance.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
cbdMD, Inc. (NYSE American: YCBD) releases its 1500 mg Tropical Mix Gummies, the latest addition to its NSF Certified for Sport® line of CBD products.
The gummies, containing 50 mg of CBD per serving, expand the company's market-leading range of Certified for Sport® products. cbdMD emphasizes its commitment to providing athletes and professionals with THC-free options that won't trigger drug tests. With the largest selection and the highest potency at the lowest prices, cbdMD aims to position itself as the premier choice for consumers. The certification assures users that products meet rigorous safety standards, allowing peace of mind for various professionals, including first responders and educators.
cbdMD, Inc. (NYSE American: YCBD) has announced the expansion of its product offerings at GNC, adding 11 new SKUs to its existing lineup of CBD products, now available in over 840 stores nationwide. This follows a successful partnership that began in August 2020. The new products include various ingestibles like CBD gummies, sleep aids, softgels, and tinctures, enhancing consumer accessibility to CBD wellness solutions. This initiative is aimed at increasing brand visibility and meeting growing consumer demand in the wellness sector.
cbdMD, Inc. (NYSE American: YCBD) announced a Citizen's Petition filed by the Natural Products Association with the FDA, requesting the removal of the drug exclusion for CBD. This move aims to create market clarity and enable cbdMD to submit a New Dietary Ingredient Notification, which could help expand its sales across mass retail channels in the U.S. The company stresses its commitment to safety and quality, supporting its petition with an extensive dossier that meets FDA requirements. The UK and EU agencies are also reviewing the company’s safety data for its products.